Generic placeholder image

Infectious Disorders - Drug Targets

Eiditor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

New Trends in Development of Antimycobacterial Compounds

Author(s): M. Biava, G C. Porretta, D. Deidda and ">R. Pompei

Volume 6 , Issue 2 , 2006

Page: [159 - 172] Pages: 14

DOI: 10.2174/187152606784112173

Price: $58

Abstract

The resurgence of tuberculosis and the surge of multidrug-resistant clinical isolates of Mycobacterium tuberculosis have reaffirmed tuberculosis as a primary public health concern. In this review we describe some new findings on the pharmacological status of fluoroquinolones derivatives (Gatifloxacin, Moxifloxacin and Sitafloxacin), new macrolides (Clarithromycin, Azithromycin and Roxithromycin), new rifamycin derivatives (Rifapentin, Rifabutin and Rifalazil) and new oxazolidinones (Linezolid and PNU 100480). We describe also other type of agents that are being developed as antimycobacterial drugs. Some of these are under clinical investigation, while others are considered to be promising candidates for future development. Among them, nitroimidazopyrans, new ketolides, Isoxyl (ISO), pyrroles derived from BM 212, Mefloquine and Diarylquinoline R207910 are discussed. We also describe the mechanism of drug resistance in mycobacteria, as well as new potential targets.

Keywords: Mycobacterium tuberculosis, Mycobacterium avium complex, tuberculosis, drug-resistance, new targets, promising drugs, anti-TB therap, drug-combinations


Rights & Permissions Print Export Cite as
Related Journals
Related eBooks
Article Metrics
4
Related Articles
© 2020 Bentham Science Publishers